Bioreactors for cell therapies: Current status and future advances

Shannon Eaker; Eytan Abraham; Julie Allickson; Thomas A. Brieva; Dolores Baksh; Thomas R.J. Heathman; Biren Mistry; Nan Zhang

doi:10.1016/j.jcyt.2016.09.011

Bioreactors for cell therapies: Current status and future advances

Shannon Eaker, Eytan Abraham, Julie Allickson, Thomas A. Brieva, Dolores Baksh, Thomas R.J. Heathman, Biren Mistry, Nan Zhang

Laboratory Medicine and Pathology

Research output: Contribution to journal › Review article › peer-review

Abstract

The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy–based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.

Original language	English (US)
Pages (from-to)	9-18
Number of pages	10
Journal	Cytotherapy
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.jcyt.2016.09.011
State	Published - Jan 1 2017

Keywords

allogeneic
autologous
bioreactor
cell culture
cell therapy
scale-out
scale-up
stem cell
tissue engineering

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology
Genetics(clinical)
Cell Biology
Transplantation
Cancer Research

Access to Document

10.1016/j.jcyt.2016.09.011

Cite this

@article{3f48a1aad94f46fd8cce37a0b0c89a11,

title = "Bioreactors for cell therapies: Current status and future advances",

abstract = "The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy–based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.",

keywords = "allogeneic, autologous, bioreactor, cell culture, cell therapy, scale-out, scale-up, stem cell, tissue engineering",

author = "Shannon Eaker and Eytan Abraham and Julie Allickson and Brieva, {Thomas A.} and Dolores Baksh and Heathman, {Thomas R.J.} and Biren Mistry and Nan Zhang",

note = "Publisher Copyright: {\textcopyright} 2017 International Society for Cellular Therapy",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.jcyt.2016.09.011",

language = "English (US)",

volume = "19",

pages = "9--18",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Bioreactors for cell therapies

T2 - Current status and future advances

AU - Eaker, Shannon

AU - Abraham, Eytan

AU - Allickson, Julie

AU - Brieva, Thomas A.

AU - Baksh, Dolores

AU - Heathman, Thomas R.J.

AU - Mistry, Biren

AU - Zhang, Nan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy–based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.

AB - The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy–based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.

KW - allogeneic

KW - autologous

KW - bioreactor

KW - cell culture

KW - cell therapy

KW - scale-out

KW - scale-up

KW - stem cell

KW - tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84993984964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993984964&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2016.09.011

DO - 10.1016/j.jcyt.2016.09.011

M3 - Review article

AN - SCOPUS:84993984964

SN - 1465-3249

VL - 19

SP - 9

EP - 18

JO - Cytotherapy

JF - Cytotherapy

IS - 1

ER -

Bioreactors for cell therapies: Current status and future advances

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this